A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging

INTRODUCTION: Changes in cerebrospinal fluid (CSF) tau and amyloid β (Aβ)42 accompany development of Alzheimer's brain pathology. Robust tau and Aβ42 immunoassays were developed to establish a tau/Aβ42 cutoff distinguishing mild-to-moderate Alzheimer's disease (AD) subjects from healthy el...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Alzheimers Dement (Amst)
Main Authors: Mo, Yi, Stromswold, Julie, Wilson, Kimberly, Holder, Daniel, Sur, Cyrille, Laterza, Omar, Savage, Mary J., Struyk, Arie, Scheltens, Philip, Teunissen, Charlotte E., Burke, James, Macaulay, S. Lance, Bråthen, Geir, Sando, Sigrid Botne, White, Linda R., Weiss, Christy, Cowes, Arturo, Bush, Michele M., DeSilva, Ganga, Darby, David G., Rainey-Smith, Stephanie R., Surls, Jackie, Sagini, Eileen, Tanen, Michael, Altman, Amy, Luthman, Johan, Egan, Michael F.
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2017
Assuntos:
CSF Biomarkers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5357677/
https://ncbi.nlm.nih.gov/pubmed/28349119
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.dadm.2017.02.004
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados